| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P433 | issue | 11 | |
| P921 | main subject | aspirin | Q18216 |
| atrial fibrillation | Q815819 | ||
| P304 | page(s) | 1237-1240 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators | |
| P478 | volume | 157 |
| Q28193940 | A benefit-risk assessment of agents used in the secondary prevention of stroke |
| Q36982811 | A practical approach to the management of patients with atrial fibrillation |
| Q24798085 | A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732] |
| Q30978475 | Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis |
| Q35142419 | Antithrombotic medication for cardioembolic stroke prevention |
| Q34362901 | Antithrombotic therapy in cardiac embolism |
| Q37222361 | Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I c |
| Q28165677 | Aspirin for the prevention of cardiovascular events in the elderly |
| Q38180390 | Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation |
| Q26851235 | Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute |
| Q77169245 | Atrial tachyarrhythmia after cardiac surgery |
| Q37690631 | Combined oral anticoagulants and antiplatelets: benefits and risks |
| Q39965332 | Comparison of aspirin and Naoxintong Capsule () with adjusted-dose warfarin in elderly patients with high-risk of non-valvular atrial fibrillation and genetic variants of vitamin K epoxide reductase |
| Q46906669 | Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists |
| Q34245296 | Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly? |
| Q34743117 | Determination of the clinical importance of study results |
| Q34746642 | Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy |
| Q28191755 | Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study |
| Q35636477 | Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials? |
| Q37442492 | Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? |
| Q36493505 | Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study |
| Q36255692 | Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study |
| Q38106663 | Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey. |
| Q33826206 | Guidelines for stroke prevention in patients with atrial fibrillation |
| Q48030210 | How prepared are pharmacists to support atrial fibrillation patients in adhering to newly prescribed oral anticoagulants? |
| Q40469080 | Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. |
| Q35790677 | Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial |
| Q50668031 | Ischemic Stroke Prevention. |
| Q28187842 | Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation |
| Q34677974 | Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation |
| Q43077501 | New antithrombotic drugs: a revolution in stroke management. |
| Q33933527 | Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes |
| Q92983756 | Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis |
| Q34551073 | Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation |
| Q28346566 | Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation |
| Q36988667 | Plasminogen activators and ischemic stroke: conditions for acute delivery |
| Q33815844 | Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs |
| Q24801915 | Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study, Etc. |
| Q33640707 | Risk factors for stroke and primary prevention of stroke in atrial fibrillation |
| Q33640743 | Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits |
| Q37087367 | Secondary stroke prevention strategies for the oldest patients: possibilities and challenges |
| Q35650380 | Selecting antithrombotic therapy for patients with atrial fibrillation |
| Q37160370 | Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? |
| Q92475887 | Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? |
| Q47137048 | Stroke Prevention for Patients with Atrial Fibrillation: Beyond the Guidelines |
| Q34027391 | Stroke prevention in atrial fibrillation |
| Q35989632 | Stroke prevention in atrial fibrillation: warfarin faces its challengers |
| Q64119729 | Stroke risk stratification in atrial fibrillation: a review of common risk factors |
| Q28175307 | Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation |
| Q28193661 | The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomized trial |
| Q33800650 | Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed |
| Q80923321 | [Anticoagulants for patients with chronic auricular fibrillation: when are they indicated?] |
Search more.